Vyome Holdings, Inc. (NASDAQ:HIND) Sees Large Increase in Short Interest

Vyome Holdings, Inc. (NASDAQ:HIND) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 76,872 shares, an increase of 272.0% from the November 30th total of 20,666 shares. Based on an average trading volume of 93,344 shares, the days-to-cover ratio is presently 0.8 days. Approximately 2.0% of the shares of the stock are short sold. Approximately 2.0% of the shares of the stock are short sold. Based on an average trading volume of 93,344 shares, the days-to-cover ratio is presently 0.8 days.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on HIND shares. Wall Street Zen raised shares of Vyome from a “sell” rating to a “hold” rating in a research note on Thursday, October 9th. Maxim Group restated a “buy” rating and set a $15.00 target price on shares of Vyome in a report on Thursday, October 2nd. Citigroup upgraded shares of Vyome to a “buy” rating in a research report on Thursday, October 2nd. Finally, Weiss Ratings reiterated a “sell (e-)” rating on shares of Vyome in a research report on Monday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Vyome currently has an average rating of “Hold” and a consensus price target of $15.00.

Vyome Price Performance

NASDAQ HIND traded up $0.13 on Thursday, hitting $3.76. 5,776 shares of the stock were exchanged, compared to its average volume of 63,751. The business’s 50-day moving average price is $5.04. Vyome has a 52-week low of $3.57 and a 52-week high of $519.00. The company has a market cap of $21.21 million, a P/E ratio of -0.03 and a beta of 1.21.

Vyome (NASDAQ:HIND) last released its earnings results on Friday, November 14th. The company reported ($3.12) earnings per share (EPS) for the quarter. Vyome had a negative net margin of 270.58% and a negative return on equity of 423.39%. The business had revenue of $0.04 million during the quarter.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.